Prognostic impact of p16 and p21 on gastroenteropancreatic neuroendocrine tumors
Open Access
- 9 October 2013
- journal article
- Published by Spandidos Publications in Oncology Letters
- Vol. 6 (6), 1641-1645
- https://doi.org/10.3892/ol.2013.1610
Abstract
Aberrant expression of the cell cycle kinase inhibitors, p16 and p21, has been associated with poor prognosis in a number of human malignancies. These proteins may also be involved in the development and progression of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The present study aimed to investigate protein levels of p16 and p21 in GEP-NETs and to evaluate their clinical significance. p16 and p21 protein expression was tested immunohistochemically in the tissue samples of 68 GEP-NETs. The association between expression and clinicopathological characteristics and overall survival was assessed. Low expression of p16 (no positive nuclear staining) was found in 37 (54%) cases and high p21 expression (≥5% positive nuclear staining) was detected in 23 (34%) cases. Low p16 protein levels indicated a poorer prognosis for patients graded as G2 subgroup in the univariate analysis (relative risk, 4.4; 95% CI, 1.8–10.6). No significant correlation was found between the expression of p21 and any of the clinicopathological variables. The present study indicates a prognostic relevance for p16 immunoreactivity. Low levels of p16 protein were associated with a shorter survival in the G2 subgroup of GEP-NETs. p21 protein expression was not identified to be useful as a predictive indicator in GEP-NETs.Keywords
This publication has 20 references indexed in Scilit:
- Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter StudyCancer Research and Treatment, 2012
- The meaning of p16ink4aexpression in tumorsCell Cycle, 2011
- The Pathologic Classification of Neuroendocrine Tumors A Review of Nomenclature, Grading, and Staging SystemsPancreas, 2010
- Incidence and management of malignant digestive endocrine tumours in a well defined French populationGut, 2004
- A 5‐decade analysis of 13,715 carcinoid tumorsCancer, 2003
- Incidence trends and risk factors of carcinoid tumorsCancer, 2001
- Epidemiology and survival in patients with carcinoid disease in the NetherlandsAnnals Of Oncology, 2001
- Regulation of G1 cyclin-dependent kinases in the mammalian cell cycleCurrent Opinion in Cell Biology, 2000
- Prognostic value and expression of p21(waf1/cip1) protein in prostate cancerThe Prostate, 1999
- THE CLASSIFICATION OF CARCINOID TUMOURSThe Lancet, 1963